Table 2 Anti-S protein antibody levels and neutralizing antibodies positivity (nABs) by treatment group before (pre-third dose) and after (post-third dose) a third dose of the SARS-CoV-2 mRNA-based vaccine
Pre-third dose | Post-third dose | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Not-treated or GCs only n = 25 | Non-biological n = 48 | Biological n = 68 | JAKi n = 15 | p value | Not-treated or GCs only n = 18 | Non-biological n = 30 | Biological n = 50 | JAKi n = 12 | p value | |
Anti-S-protein antibody (BAU/ml) | 761 [43, 83890] | 857 [14, 40700] | 288 [0, 87880] | 534 [34, 85340] | 0.0111 | 11445 [1002, 74400] | 10850 [433, 112590] | 7966 [0, 137780] | 6374 [393, 166760] | 0.8029 |
Wild type—Positive | 19 (76.0%) | 37 (77.1%) | 37 (54.4%) | 10 (66.7%) | 0.0523 | 18 (100%) | 30 (100%) | 45 (90.0%) | 12 (100%) | 0.1561 |
B.1.1.529—Positive | 4 (16.0%) | 8 (16.7%) | 3 (4.4%) | 2 (13.3%) | 0.09088 | 10 (55.6%) | 18 (60.0%) | 25 (50.0%) | 7 (58.3%) | 0.8489 |
B.1.1.7—Positive | 11 (44.0%) | 23 (47.9%) | 19 (27.9%) | 5 (33.3%) | 0.1380 | 17 (94.4%) | 29 (96.7%) | 44 (88.0%) | 10 (83.3%) | 0.3733 |
B.1.351—Positive | 10 (41.7%) | 19 (39.6%) | 12 (17.9%) | 3 (20.0%) | 0.0265 | 14 (87.5%) | 29 (96.7%) | 41 (83.7%) | 10 (83.3%) | 0.3002 |
B.1.617.2—Positive | 11 (44.0%) | 21 (43.8%) | 16 (23.5%) | 4 (26.7%) | 0.0730 | 17 (94.4%) | 29 (96.7%) | 43 (86.0%) | 10 (83.3%) | 0.3146 |
P.1—Positive | 10 (40.0%) | 18 (37.5%) | 15 (22.1%) | 4 (26.7%) | 0.1959 | 14 (77.8%) | 28 (93.3%) | 42 (84.0%) | 10 (83.3%) | 0.45344 |